Drug Trial Radar · NCT03154619
Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers
Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 2016
Primary completion
Apr 4, 2019
Study completion Apr 1, 2021
Sponsor
- Lead sponsor
- SerenaGroup, Inc.Research network
- Sponsor type
- Research network
- Collaborators
- TR Therapeutics
- First posted
- May 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.
Conditions
- Venous Leg Ulcer
Interventions
0.1% TR 987Drug
TR 987 0.1%
Placebo gelDrug
Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to complete wound closureTime frame: 12 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
New Hope Podiatry Clinic
Los Angeles, California
Barry University Clinical Research
North Miami Beach, Florida
Royal Research Corp
Pembroke Pines, Florida
Deborah Heart and Lung Center
Browns Mills, New Jersey
Cleveland Foot and Ankle Clinic
Cleveland, Ohio
The Foot and Ankle Wellness Center
Ford City, Pennsylvania
Armstrong County Memorial Hospital
Kittanning, Pennsylvania
SerenaGroup Research Institute
Pittsburgh, Pennsylvania
Martin Foot and Ankle
York, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.